Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715339 | 1.00 | CTSL (0.38) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL2714853 | 0.78 | AAK1 (0.39) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL2714856 | 0.78 | AAK1 (0.39) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL18925285 | 0.77 | PLAU (0.35) | CTSLCTSSCTSBCTSKMMP1 | |
| SCHEMBL2714211 | 0.76 | CTSL (0.33) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL2714205 | 0.76 | CTSL (0.33) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL2712370 | 0.76 | CNR2 (0.40) | CTSLCNR2ADRB2CNR1 | |
| SCHEMBL2714341 | 0.76 | CTSS (0.41) | CTSLCTSSCTSBCTSKMMP1 | |
| SCHEMBL2714346 | 0.76 | CTSS (0.41) | CTSLCTSSCTSBCTSKMMP1 | |
| SCHEMBL2712373 | 0.76 | CNR2 (0.40) | CTSLCNR2ADRB2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902688-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| CN-103282352-B | Benzamides and nicotinamide as SYK regulator | 波托拉医药品公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2635556-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012061418-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | CTSL 1801/4885CTSS 1406/4885CTSB 1416/4885 |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | CTSL 2548/4885CTSS 3149/4885CTSB 2593/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | CTSL 1801/4885CTSS 1406/4885CTSB 1416/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | CTSL 1801/4885CTSS 1406/4885CTSB 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.